<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04103450</url>
  </required_header>
  <id_info>
    <org_study_id>URO-901-3006</org_study_id>
    <secondary_id>2018-003136-72</secondary_id>
    <nct_id>NCT04103450</nct_id>
  </id_info>
  <brief_title>Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)</brief_title>
  <official_title>A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Urovant Sciences GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Urovant Sciences GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the long-term safety of vibegron when dosed up to 52 weeks in men with&#xD;
      overactive bladder (OAB) symptoms on pharmacological therapy for Benign Prostatic Hyperplasia&#xD;
      (BPH) who previously completed treatment in Study URO-901-3005 (NCT03902080).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">September 19, 2019</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Long-term extension</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with any Adverse Event</measure>
    <time_frame>From signing of informed consent up to 21 days after the last dose of study drug (up to approximately 52 weeks)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with any Clinically Significant Clinical Laboratory Value</measure>
    <time_frame>From signing of informed consent up to 21 days after the last dose of study drug (up to approximately 52 weeks)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with any Clinically Significant Vital Sign Assessment</measure>
    <time_frame>From signing of informed consent up to 21 days after the last dose of study drug (up to approximately 52 weeks)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline at Week 52 in the Average Number of Micturition Episodes per Day</measure>
    <time_frame>Baseline; Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline at Week 52 in the Average Number of Urgency Episodes per Day</measure>
    <time_frame>Baseline; Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline at Week 52 in the Average Number of Nocturia Episodes per Night</measure>
    <time_frame>Baseline; Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline at Week 52 in the Average Number of Urge Urinary Incontinence Episodes per Day in Participants with Incontinence at Study URO-901-3005 Baseline</measure>
    <time_frame>Baseline; Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline at Week 52 in the Average of the International Prostate Symptom Score (IPSS) Storage Score (1-week recall)</measure>
    <time_frame>Baseline; Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline at Week 52 in the Average Volume Voided per Micturition</measure>
    <time_frame>Baseline; Week 52</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Overactive Bladder</condition>
  <arm_group>
    <arm_group_label>Vibegron</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 75 milligrams (mg) vibegron orally once daily (QD).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vibegron</intervention_name>
    <description>oral administration</description>
    <arm_group_label>Vibegron</arm_group_label>
    <other_name>RVT-901</other_name>
    <other_name>MK-4618</other_name>
    <other_name>KRP-114V</other_name>
    <other_name>URO-901</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant has completed participation of the 24-week double-blind treatment period&#xD;
             in Study URO-901-3005 (NCT03902080) and demonstrated compliance with the study&#xD;
             procedures and study medication schedule in the opinion of the investigator.&#xD;
&#xD;
          -  Participant is capable of giving written informed consent, which includes compliance&#xD;
             with the requirements and restrictions listed in the consent form.&#xD;
&#xD;
          -  Participant has the ability to continue to receive a stable dose of Benign Prostatic&#xD;
             Hyperplasia (BPH) treatment with either a) alpha blocker monotherapy or b) alpha&#xD;
             blocker +5-ARI.&#xD;
&#xD;
          -  In the opinion of the investigator, the participant is able and willing to comply with&#xD;
             the requirements of the protocol, including completing study questionnaires and the&#xD;
             Bladder Diary.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participant experienced any Serious Adverse Event in Study URO-901-3005 that was&#xD;
             reported as &quot;possibly or probably related&quot; to study treatment by the investigator.&#xD;
&#xD;
          -  Participant is using any prohibited medications&#xD;
&#xD;
          -  Participant has uncontrolled hyperglycemia (defined as fasting blood glucose &gt;150&#xD;
             milligrams per deciliter [mg/dL] or 8.33 millimoles per Liter [mmol/L] and/or&#xD;
             non-fasting blood glucose &gt;200 mg/dL or 11.1 mmol/L) based on most recent available&#xD;
             lab results in Study URO-901-3005 or uncontrolled in the opinion of the investigator.&#xD;
&#xD;
          -  Participant has uncontrolled hypertension (systolic blood pressure of ≥180 millimeters&#xD;
             of mercury [mmHg] and/or diastolic blood pressure of ≥100 mmHg) or has a resting heart&#xD;
             rate (by pulse) &gt;100 beats per minute.&#xD;
&#xD;
          -  Participant has systolic blood pressures ≥160 mmHg but &lt;180 mmHg, unless deemed by the&#xD;
             investigator as safe to proceed in this study and able to complete the study per&#xD;
             protocol.&#xD;
&#xD;
          -  Participant has current evidence of any clinically significant condition, therapy, lab&#xD;
             abnormality, or other circumstances that might, in the opinion of the investigator,&#xD;
             confound the results of the study, interfere with the participant's ability to comply&#xD;
             with study procedures, or make participation in the study not in the participant's&#xD;
             best interest.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rachael Jankowich, RN, MSN</last_name>
    <role>Study Director</role>
    <affiliation>Urovant Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Private Practice</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials Research</name>
      <address>
        <city>Lincoln</city>
        <state>California</state>
        <zip>95648</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American Institute of Research</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tri Valley Urology Medical Group</name>
      <address>
        <city>Murrieta</city>
        <state>California</state>
        <zip>92562</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern California Research Corp</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95821</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Diego Clinical Trials</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skyline Urology</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imagine Research of Palm Beach County - Urology</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampa Bay Medical Research</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quantum Clinical Trials</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology Center Of Florida</name>
      <address>
        <city>Pompano Beach</city>
        <state>Florida</state>
        <zip>33060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Precision Clinical Research</name>
      <address>
        <city>Sunrise</city>
        <state>Florida</state>
        <zip>33351</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of Central Florida</name>
      <address>
        <city>Winter Haven</city>
        <state>Florida</state>
        <zip>33880</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DelRicht Research</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Urology, LLC</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Clinical Trials Inc - Urology</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bay State Clinical Trials, Inc.</name>
      <address>
        <city>Watertown</city>
        <state>Massachusetts</state>
        <zip>02472</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beaumont Hospital Royal Oak - Urology Research</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CentraCare Clinic - Adult &amp; Pediatric Urology</name>
      <address>
        <city>Sartell</city>
        <state>Minnesota</state>
        <zip>56377</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Poplar Bluff Urology</name>
      <address>
        <city>Poplar Bluff</city>
        <state>Missouri</state>
        <zip>63901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adult &amp; Pediatric Urology P.C. - Urology</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Excel Clinical Research - Internal Medicine</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Urology Group, LLC</name>
      <address>
        <city>Edison</city>
        <state>New Jersey</state>
        <zip>08837</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Jersey Urology NJU</name>
      <address>
        <city>Englewood</city>
        <state>New Jersey</state>
        <zip>07631</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urological Surgeons of Long Island</name>
      <address>
        <city>Garden City</city>
        <state>New York</state>
        <zip>11530</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Solutions</name>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <zip>44130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advances In Health, Inc.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wasatch Clinical Research LLC</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Urology Research Center</name>
      <address>
        <city>Burien</city>
        <state>Washington</state>
        <zip>98166</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>September 23, 2019</study_first_submitted>
  <study_first_submitted_qc>September 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2019</study_first_posted>
  <last_update_submitted>July 7, 2021</last_update_submitted>
  <last_update_submitted_qc>July 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Overactive Bladder</keyword>
  <keyword>Benign Prostatic Hyperplasia</keyword>
  <keyword>Vibegron</keyword>
  <keyword>Beta-3 adrenergic receptor (β3-AR)</keyword>
  <keyword>β3-AR agonist</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Urovant is committed to sharing patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Data requests will be reviewed and approved on the basis of scientific merit. All data provided will be anonymized according to applicable laws and regulations.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>The data will be made available within 24 months after study completion and will be accessible for a time frame appropriate for the approved proposal.</ipd_time_frame>
    <ipd_access_criteria>Access to these clinical trial data can be requested by emailing medinfo@urovant.com and will be provided following Urovant review and approval of a research proposal and execution of a Data Sharing Agreement (DSA).</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

